Cargando…
Cost-Effectiveness of Baricitinib Compared With Standard of Care: A Modeling Study in Hospitalized Patients With COVID-19 in the United States
PURPOSE: In the Phase III COV-BARRIER (Efficacy and Safety of Baricitinib for the Treatment of Hospitalised Adults With COVID-19) trial, treatment with baricitinib, an oral selective Janus kinase 1/2 inhibitor, in addition to standard of care (SOC), was associated with significantly reduced mortalit...
Autores principales: | Ohsfeldt, Robert, Kelton, Kari, Klein, Tim, Belger, Mark, Mc Collam, Patrick L., Spiro, Theodore, Burge, Russel, Ahuja, Neera |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487786/ https://www.ncbi.nlm.nih.gov/pubmed/34732289 http://dx.doi.org/10.1016/j.clinthera.2021.09.016 |
Ejemplares similares
-
Cost-Effectiveness of Combination of Baricitinib and Remdesivir in Hospitalized Patients with COVID-19 in the United States: A Modelling Study
por: Kelton, Kari, et al.
Publicado: (2021) -
Inpatient Hospital Costs for COVID-19 Patients in the United States
por: Ohsfeldt, Robert L., et al.
Publicado: (2021) -
Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis
por: Urowitz, Murray B, et al.
Publicado: (2019) -
The Impact of the COVID-19 Pandemic on Vascular Surgery Trainees in the United States
por: Johnson, Adam P., et al.
Publicado: (2021) -
Challenges in the Practice of Sexual Medicine in the Time of COVID-19 in the United States
por: Shindel, Alan W., et al.
Publicado: (2020)